Quantification of hormesis in anticancer-agent dose-responses

Dose-Response

Volumn 7, Issue 2, 2009, Pages 160-171

  Nascarella, Marc A ^a   Stanek, Edward ^a   Hoffmann, George R ^b   Calabrese, Edward J ^c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Department of Biology   (United States)

^c GRADIENT   (United States)

Author keywords

Anti tumor; Biphasic; Hormesis; Low dose; Threshold; Yeast

Indexed keywords

EID: 70349324825     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.08-025.Nascarella     Document Type: Article

References (13)

1. Calabrese EJ, Stanek EJ, Nascarella MA, and Hoffmann GR. 2008. Hormesis predicts low-dose responses better than threshold models. Int J Tox 27:369-378
2. Calabrese EJ, Staudenmayer JW, Stanek EJ III, and Hoffmann GR. 2006a. Hormesis outperforms threshold model in National Cancer Institute antitumor drug screening database. Toxicol Sci 94:368-378
3. Calabrese EJ, Staudenmayer JW, and Stanek EJ III. 2006b. Drug development and hormesis: Changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel 9:117-123
4. Calabrese EJ and Blain R. 2005. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: An overview. Toxicol Appl Pharmacol 202:289-301
5. Calabrese EJ. 2005. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 35:463-582
6. Calabrese EJ and v1Baldwin LA. 2003. Hormesis at the National Toxicology Program (NTP) : Evidence of hormetic dose responses in NTP dose-range studies. Nonlinearity Biol Toxicol Med 1:455-467
7. Calabrese EJ and Baldwin LA. 2002. Defining Hormesis. Hum Exper Toxicol 21:91-97
8. Calabrese EJ. 2001. Overcompensation stimulation: a mechanism for hormetic effects. Crit Rev Toxicol 31:425-470
9. Calabrese EJ and Baldwin LA. 1997. A quantitatively-based methodology for the evaluation of chemical hormesis. Hum Ecol Risk Assess 3:545-554
10. Holbeck SL and Simon J. 2007. The FHCRC/NCI yeast anticancer drug screen. In: Nitiss JL and Heitman J (eds), Yeast as a Tool in Cancer Research, pp 315-346. Springer, Dordrecht, The Netherlands
11. Holbeck SL. 2004. Update on NCI in vitro drug screen utilities. Eur J Cancer 40:785-793
12. NCI (National Cancer Institute). 2007. Publicly available data from the National Cancer Institute Yeast Anticancer Drug Screen, Experimental Design. Available at http://dtp. nci.nih.gov/yacds/exp-design.html
13. Szabadi E. 1977. A model of two functionally antagonistic receptor populations activated by the same agonist. J Theor Biol 69:101-112